Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease [Yahoo! Fina...
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: Yahoo! Finance
editorial-team@simplywallst.com (Simply Wall St) Fri, February 14, 2025 at 3:01 PM GMT+1 4 min read In This Article NAMS NAMSW Key Insights NewAmsterdam Pharma's significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 6 investors have a majority stake in the company with 53% ownership 34% of NewAmsterdam Pharma is held by Institutions If you want to know who really controls NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ), then you'll have to look at the makeup of its share registry. We can see that private equity firms own the lion's share in the company with 42% ownership. Put another way, the group faces the maximum upside potential (o
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma (NASDAQ: NAMS) was given a new $41.00 price target on by analysts at UBS Group AG.MarketBeat
- NewAmsterdam Pharma (NASDAQ: NAMS) had its price target raised by analysts at Scotiabank from $47.00 to $52.00. They now have a "sector outperform" rating on the stock.MarketBeat
- NewAmsterdam Pharma (NASDAQ: NAMS) had its price target lowered by analysts at Needham & Company LLC from $46.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
- NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MarchGlobeNewswire
NAMS
Sec Filings
- 3/11/25 - Form EFFECT
- 3/10/25 - Form 424B3
- 3/6/25 - Form 4
- NAMS's page on the SEC website